India's Zydus Lifesciences more than doubles profit on US sales growth

The pharmaceutical company's consolidated net profit rose to 10.87 billion rupees ($131.3 million) in the quarter ended June 30, compared with 5.18 billion rupees a year earlier. Its U.S formulations business saw a revenue growth of 57.4 per cent to 24.54 billion rupees, while India formulations grew by 9.1 per cent to 12.27 billion rupees. India and U.S. sales make up 38 per cent and 48 per cent of Zydus' total revenue, respectively.